Questões de Concurso
Comentadas para analista de mercado de capitais
Foram encontradas 77 questões
Resolva questões gratuitamente!
Junte-se a mais de 4 milhões de concurseiros!
Ano: 2010
Banca:
ESAF
Órgão:
CVM
Provas:
ESAF - 2010 - CVM - Analista de Mercado de Capitais - prova 2
|
ESAF - 2010 - CVM - Analista - Normas Contábeis e de Auditoria - prova 2 |
ESAF - 2010 - CVM - Inspetor - prova 2 |
Q91975
Contabilidade Geral
Aponte abaixo a opção que contém uma assertiva
incorreta.
Ano: 2010
Banca:
ESAF
Órgão:
CVM
Provas:
ESAF - 2010 - CVM - Analista de Mercado de Capitais - prova 1
|
ESAF - 2010 - CVM - Analista - Normas Contábeis e de Auditoria - prova 1 |
Q91962
Matemática Financeira
Um certo número de bônus de valor de face de 1.000 USD, e constituído por 12 cupons semestrais no valor de 50 USD cada um, é lançado por uma empresa no mercado internacional com o objetivo de levantar um empréstimo. A empresa se compromete a pagar o valor de cada cupom no fim de cada semestre e o valor de face do bônus ao fim de seis anos juntamente com o valor do último cupom. Caso cada bônus seja vendido hoje por 841,15 USD, já descontadas as despesas de lançamento, qual o valor mais próximo da taxa de juros paga pela empresa lançadora do bônus?
Ano: 2010
Banca:
ESAF
Órgão:
CVM
Provas:
ESAF - 2010 - CVM - Analista de Mercado de Capitais - prova 1
|
ESAF - 2010 - CVM - Analista - Normas Contábeis e de Auditoria - prova 1 |
ESAF - 2010 - CVM - Inspetor - prova 1 |
Q91961
Matemática Financeira
Um título é descontado quatro meses antes do seu vencimento a uma taxa de desconto de 5% ao mês, sendo o valor do desconto racional composto calculado em R$ 4.310,00. Marque o valor mais próximo do valor nominal do título.
Ano: 2010
Banca:
ESAF
Órgão:
CVM
Provas:
ESAF - 2010 - CVM - Analista de Mercado de Capitais - prova 1
|
ESAF - 2010 - CVM - Analista - Normas Contábeis e de Auditoria - prova 1 |
Q91956
Matemática Financeira
Um investidor fez uma aplicação em um título com rentabilidade pós-fixada por um prazo de três meses a uma taxa de juros simples de 18% ao ano. O índice de correção a ser aplicado ao montante passou de 80, no início, a 83,2, no fim do prazo. Qual o valor mais próximo da rentabilidade total do título nesse prazo?
Ano: 2010
Banca:
ESAF
Órgão:
CVM
Provas:
ESAF - 2010 - CVM - Analista de TIC - Infraestrutura - prova 1
|
ESAF - 2010 - CVM - Analista de Mercado de Capitais - prova 1 |
ESAF - 2010 - CVM - Analista - Planejamento e Execução Financeira - Contador - prova 1 |
ESAF - 2010 - CVM - Analista - Normas Contábeis e de Auditoria - prova 1 |
Q91947
Português
Assinale a opção em que ocorre erro na transcrição e adaptação do texto de Conjuntura Econômica, de setembro de 2010 – vol. 64 – n. 9.
O mecanismo de câmbio flutuante, quando acompanhado de razoável mobilidade de capitais, provê um meio automático através do qual o equilíbrio se configura(a). Elevações de consumo ou investimento da parte de residentes geram pequenas elevações de juros que majoram a entrada de capitais externos, desta forma valorizando(b) a moeda doméstica. Tal valorização reduz as exportações e aumenta as importações, meio pelos quais(c) se compensa, liquidamente, a preços possivelmente constantes, o acréscimo inicial de procura por bens e serviços provocado por possíveis expansões de absorção interna. Tudo pode ocorrer muito bem até o ponto em que(d) os déficits na conta corrente do balanço de pagamentos passem(e) a gerar um montante do passivo externo líquido do país, que dá início a um processo de desconfiança dos provedores de crédito líquido em moeda estrangeira. Quando isso ocorre, há uma necessidade de reverter tais déficits, configurando, em última instância, que o sucesso no combate à inflação no período inicial pode ter significado, em boa parte, uma transferência de problemas para o futuro.
O mecanismo de câmbio flutuante, quando acompanhado de razoável mobilidade de capitais, provê um meio automático através do qual o equilíbrio se configura(a). Elevações de consumo ou investimento da parte de residentes geram pequenas elevações de juros que majoram a entrada de capitais externos, desta forma valorizando(b) a moeda doméstica. Tal valorização reduz as exportações e aumenta as importações, meio pelos quais(c) se compensa, liquidamente, a preços possivelmente constantes, o acréscimo inicial de procura por bens e serviços provocado por possíveis expansões de absorção interna. Tudo pode ocorrer muito bem até o ponto em que(d) os déficits na conta corrente do balanço de pagamentos passem(e) a gerar um montante do passivo externo líquido do país, que dá início a um processo de desconfiança dos provedores de crédito líquido em moeda estrangeira. Quando isso ocorre, há uma necessidade de reverter tais déficits, configurando, em última instância, que o sucesso no combate à inflação no período inicial pode ter significado, em boa parte, uma transferência de problemas para o futuro.
Ano: 2010
Banca:
ESAF
Órgão:
CVM
Provas:
ESAF - 2010 - CVM - Analista de TIC - Infraestrutura - prova 1
|
ESAF - 2010 - CVM - Analista de Mercado de Capitais - prova 1 |
ESAF - 2010 - CVM - Analista de Sistemas - prova 1 |
Q91869
Português
Assinale a opção que, na sequência, preenche corretamente as lacunas do texto, de modo a manter a coesão e a coerência entre as ideias.
Quando uma pessoa compra uma ação de uma empresa, torna-se sócia dessa companhia. Signi?ca que ___(1)___ se bene?cia de seu sucesso ou sofre as consequências ___(2)___ fracasso. Funciona assim: ao ganhar dinheiro, uma corporação com ações cotadas em bolsa remunera melhor seus acionistas. O inverso também é verdadeiro. No mercado acionário, é impossível dizer ____(3)____ um investimento dará retorno líquido e certo. Uma série de fatores ____(4)____ levada em conta. Desde ____(5)____ que a empresa pode controlar (lançamento de produtos e projetos de sucesso, boa performance ?nanceira) até aspectos externos (crise global, acidentes), ____(6)____ muitas vezes independem de uma boa administração da companhia.
Quando uma pessoa compra uma ação de uma empresa, torna-se sócia dessa companhia. Signi?ca que ___(1)___ se bene?cia de seu sucesso ou sofre as consequências ___(2)___ fracasso. Funciona assim: ao ganhar dinheiro, uma corporação com ações cotadas em bolsa remunera melhor seus acionistas. O inverso também é verdadeiro. No mercado acionário, é impossível dizer ____(3)____ um investimento dará retorno líquido e certo. Uma série de fatores ____(4)____ levada em conta. Desde ____(5)____ que a empresa pode controlar (lançamento de produtos e projetos de sucesso, boa performance ?nanceira) até aspectos externos (crise global, acidentes), ____(6)____ muitas vezes independem de uma boa administração da companhia.
Q2242624
Inglês
Texto associado
The hard cell
Thanks to politics, stem cell research in the United States is suffering. But not so in Sweden, which is poised to capture what could be the biggest new market to hit biotech in a decade.
By Stephan Herrera
February 13, 2003
New York, January 1, 2006:
Sweden announces that one of its biotechnology companies is the first in the world to enter clinical trials with a new drug that could cure Alzheimer's disease. Four years ago this type of research was all but stopped in the United States by political and ethical questions − which is ....61.... Sweden now seems in the best position to capture a $25 billion market.
Any day now, the U.S. Congress is expected to pass a sweeping new law that could dramatically inhibit researchers from working with stem cells taken from human embryos. Such cells, which can be used to grow a whole host of new cells and organs, could fundamentally change the way we treat heretofore intractable maladies like Alzheimer's disease, Parkinson's disease, cancer, stroke, liver failure, and heart disease. The only problem is that these cells by definition are derived from human embryos, many of which are cloned or come from unused fetuses collected at fertility clinics. The argument, from a certain segment of the American political spectrum, is that ....62.... methods are morally wrong. They are ....63.... a form of abortion or an activity that could eventually lead to human cloning.
Those working in stem cell research say the short-term effect of the legislation will be to further chill all forms of scientific inquiry and commercialization efforts in the field. Entrepreneurs and investors are already eschewing such research − in large part because of the additional uncertainty and risk that politics introduce.
Of the nearly 50 private stem cell companies in the United States, only a handful are still viable. Meanwhile, across the Atlantic, Sweden has avoided many of the political and ethical quagmires surrounding this type of research. It currently has 40 private stem cell companies, a number that's growing. Sweden's leading research universities have 32 percent of the world's stem cell inventory, close on the heels of the United States' 35 percent.
Sweden, say analysts, is now in the best position to capture a worldwide market for drugs based on stem cell therapies that could grow to $25 billion in the next three to five years − nearly equal to the whole biotech industry at present. This estimate doesn't even address the market for stem cells capable of repairing damaged vital organs like the brain, heart, and kidneys. If the United States offers an object lesson of what can happen when scientific inquiry and investment capital fall victim to politics, Sweden and its leading stem cell startup, NeuroNova, offer the opposite example. How odd that the United States, which for generations has been the envy of the world for its progressive views of science and commercialization, should now have a biomedical climate chillier than a Swedish winter.
One company feeling a lot of pain is StemCells, which at first glance seems to have it all: founding scientists include Stanford's Dr. Weissman and Fred Gage of the Salk Institute in La Jolla, California. An equally well-regarded expert in the treatment of Alzheimer's, Dr. Gage spent five years in Sweden as a researcher and now sits on a national committee on stem cell research there. The firm's chairman is Roger Perlmutter, Amgen's head of research.
Yet over the past two years, none of management's efforts to help investors and even critics reconsider the stem cell field have worked. At press time, the stock was thinly traded and sitting in the neighborhood of 50 cents. With less than $15 million in cash, the company likely won't exist at this time next year. (CEO Martin McGlynn, who joined the firm in January 2001, would not talk to Red Herring, despite repeated efforts.)
Some observers on Wall Street are asking, If StemCells can't make it, who can? Geron, the only other publicly held stem cell firm to speak of, is in a fix, too. The company's stock price is also moribund, at $3.85 per share. Thanks to some capital infusions a few years ago, when money came easy, Geron still has $40 million on hand, but by the end of next year, that too will likely be gone. Once a media darling, Geron focuses on diagnostic tests and drugs derived from stem cells, a strategy that's not going well. For the nine months ended last September, revenue fell 68 percent to $955,000 and net loss widened 18 percent to $26.7 million. The company's financials were also hit hard after it terminated an agreement with Pharmacia and acquired research technology from Lynx Therapeutics, which Geron bought in a desperate attempt to be seen as something more than just a stem cell company.
The situation is quite different, however, for Sweden's NeuroNova, which has 30 academic partners and a staff of 20. NeuroNova is working on ways to inject stem cells into the human brain to trigger a process called neurogenesis (the growth of new neural cells), which could combat diseases like Parkinson's, Alzheimer's, and even schizophrenia.
If NeuroNova is the first to develop a drug capable of treating one of several central nervous system disorders − by far the most lucrative after heart disease products − it will have done so not because it raised more money or got more media buzz than the rest. It will have succeeded because the science is solid, and academe, government, and the investment community are supportive. Meanwhile, the United States will look on with envy and wonder how it, a country known for its entrepreneurial innovation, ever got so short-sighted.
(Adapted from http://www.redherring.com/investor/2003/02/biotech021303.html)
O autor do artigo
Q2242623
Inglês
Texto associado
The hard cell
Thanks to politics, stem cell research in the United States is suffering. But not so in Sweden, which is poised to capture what could be the biggest new market to hit biotech in a decade.
By Stephan Herrera
February 13, 2003
New York, January 1, 2006:
Sweden announces that one of its biotechnology companies is the first in the world to enter clinical trials with a new drug that could cure Alzheimer's disease. Four years ago this type of research was all but stopped in the United States by political and ethical questions − which is ....61.... Sweden now seems in the best position to capture a $25 billion market.
Any day now, the U.S. Congress is expected to pass a sweeping new law that could dramatically inhibit researchers from working with stem cells taken from human embryos. Such cells, which can be used to grow a whole host of new cells and organs, could fundamentally change the way we treat heretofore intractable maladies like Alzheimer's disease, Parkinson's disease, cancer, stroke, liver failure, and heart disease. The only problem is that these cells by definition are derived from human embryos, many of which are cloned or come from unused fetuses collected at fertility clinics. The argument, from a certain segment of the American political spectrum, is that ....62.... methods are morally wrong. They are ....63.... a form of abortion or an activity that could eventually lead to human cloning.
Those working in stem cell research say the short-term effect of the legislation will be to further chill all forms of scientific inquiry and commercialization efforts in the field. Entrepreneurs and investors are already eschewing such research − in large part because of the additional uncertainty and risk that politics introduce.
Of the nearly 50 private stem cell companies in the United States, only a handful are still viable. Meanwhile, across the Atlantic, Sweden has avoided many of the political and ethical quagmires surrounding this type of research. It currently has 40 private stem cell companies, a number that's growing. Sweden's leading research universities have 32 percent of the world's stem cell inventory, close on the heels of the United States' 35 percent.
Sweden, say analysts, is now in the best position to capture a worldwide market for drugs based on stem cell therapies that could grow to $25 billion in the next three to five years − nearly equal to the whole biotech industry at present. This estimate doesn't even address the market for stem cells capable of repairing damaged vital organs like the brain, heart, and kidneys. If the United States offers an object lesson of what can happen when scientific inquiry and investment capital fall victim to politics, Sweden and its leading stem cell startup, NeuroNova, offer the opposite example. How odd that the United States, which for generations has been the envy of the world for its progressive views of science and commercialization, should now have a biomedical climate chillier than a Swedish winter.
One company feeling a lot of pain is StemCells, which at first glance seems to have it all: founding scientists include Stanford's Dr. Weissman and Fred Gage of the Salk Institute in La Jolla, California. An equally well-regarded expert in the treatment of Alzheimer's, Dr. Gage spent five years in Sweden as a researcher and now sits on a national committee on stem cell research there. The firm's chairman is Roger Perlmutter, Amgen's head of research.
Yet over the past two years, none of management's efforts to help investors and even critics reconsider the stem cell field have worked. At press time, the stock was thinly traded and sitting in the neighborhood of 50 cents. With less than $15 million in cash, the company likely won't exist at this time next year. (CEO Martin McGlynn, who joined the firm in January 2001, would not talk to Red Herring, despite repeated efforts.)
Some observers on Wall Street are asking, If StemCells can't make it, who can? Geron, the only other publicly held stem cell firm to speak of, is in a fix, too. The company's stock price is also moribund, at $3.85 per share. Thanks to some capital infusions a few years ago, when money came easy, Geron still has $40 million on hand, but by the end of next year, that too will likely be gone. Once a media darling, Geron focuses on diagnostic tests and drugs derived from stem cells, a strategy that's not going well. For the nine months ended last September, revenue fell 68 percent to $955,000 and net loss widened 18 percent to $26.7 million. The company's financials were also hit hard after it terminated an agreement with Pharmacia and acquired research technology from Lynx Therapeutics, which Geron bought in a desperate attempt to be seen as something more than just a stem cell company.
The situation is quite different, however, for Sweden's NeuroNova, which has 30 academic partners and a staff of 20. NeuroNova is working on ways to inject stem cells into the human brain to trigger a process called neurogenesis (the growth of new neural cells), which could combat diseases like Parkinson's, Alzheimer's, and even schizophrenia.
If NeuroNova is the first to develop a drug capable of treating one of several central nervous system disorders − by far the most lucrative after heart disease products − it will have done so not because it raised more money or got more media buzz than the rest. It will have succeeded because the science is solid, and academe, government, and the investment community are supportive. Meanwhile, the United States will look on with envy and wonder how it, a country known for its entrepreneurial innovation, ever got so short-sighted.
(Adapted from http://www.redherring.com/investor/2003/02/biotech021303.html)
Segundo o texto, a Geron
Q2242622
Inglês
Texto associado
The hard cell
Thanks to politics, stem cell research in the United States is suffering. But not so in Sweden, which is poised to capture what could be the biggest new market to hit biotech in a decade.
By Stephan Herrera
February 13, 2003
New York, January 1, 2006:
Sweden announces that one of its biotechnology companies is the first in the world to enter clinical trials with a new drug that could cure Alzheimer's disease. Four years ago this type of research was all but stopped in the United States by political and ethical questions − which is ....61.... Sweden now seems in the best position to capture a $25 billion market.
Any day now, the U.S. Congress is expected to pass a sweeping new law that could dramatically inhibit researchers from working with stem cells taken from human embryos. Such cells, which can be used to grow a whole host of new cells and organs, could fundamentally change the way we treat heretofore intractable maladies like Alzheimer's disease, Parkinson's disease, cancer, stroke, liver failure, and heart disease. The only problem is that these cells by definition are derived from human embryos, many of which are cloned or come from unused fetuses collected at fertility clinics. The argument, from a certain segment of the American political spectrum, is that ....62.... methods are morally wrong. They are ....63.... a form of abortion or an activity that could eventually lead to human cloning.
Those working in stem cell research say the short-term effect of the legislation will be to further chill all forms of scientific inquiry and commercialization efforts in the field. Entrepreneurs and investors are already eschewing such research − in large part because of the additional uncertainty and risk that politics introduce.
Of the nearly 50 private stem cell companies in the United States, only a handful are still viable. Meanwhile, across the Atlantic, Sweden has avoided many of the political and ethical quagmires surrounding this type of research. It currently has 40 private stem cell companies, a number that's growing. Sweden's leading research universities have 32 percent of the world's stem cell inventory, close on the heels of the United States' 35 percent.
Sweden, say analysts, is now in the best position to capture a worldwide market for drugs based on stem cell therapies that could grow to $25 billion in the next three to five years − nearly equal to the whole biotech industry at present. This estimate doesn't even address the market for stem cells capable of repairing damaged vital organs like the brain, heart, and kidneys. If the United States offers an object lesson of what can happen when scientific inquiry and investment capital fall victim to politics, Sweden and its leading stem cell startup, NeuroNova, offer the opposite example. How odd that the United States, which for generations has been the envy of the world for its progressive views of science and commercialization, should now have a biomedical climate chillier than a Swedish winter.
One company feeling a lot of pain is StemCells, which at first glance seems to have it all: founding scientists include Stanford's Dr. Weissman and Fred Gage of the Salk Institute in La Jolla, California. An equally well-regarded expert in the treatment of Alzheimer's, Dr. Gage spent five years in Sweden as a researcher and now sits on a national committee on stem cell research there. The firm's chairman is Roger Perlmutter, Amgen's head of research.
Yet over the past two years, none of management's efforts to help investors and even critics reconsider the stem cell field have worked. At press time, the stock was thinly traded and sitting in the neighborhood of 50 cents. With less than $15 million in cash, the company likely won't exist at this time next year. (CEO Martin McGlynn, who joined the firm in January 2001, would not talk to Red Herring, despite repeated efforts.)
Some observers on Wall Street are asking, If StemCells can't make it, who can? Geron, the only other publicly held stem cell firm to speak of, is in a fix, too. The company's stock price is also moribund, at $3.85 per share. Thanks to some capital infusions a few years ago, when money came easy, Geron still has $40 million on hand, but by the end of next year, that too will likely be gone. Once a media darling, Geron focuses on diagnostic tests and drugs derived from stem cells, a strategy that's not going well. For the nine months ended last September, revenue fell 68 percent to $955,000 and net loss widened 18 percent to $26.7 million. The company's financials were also hit hard after it terminated an agreement with Pharmacia and acquired research technology from Lynx Therapeutics, which Geron bought in a desperate attempt to be seen as something more than just a stem cell company.
The situation is quite different, however, for Sweden's NeuroNova, which has 30 academic partners and a staff of 20. NeuroNova is working on ways to inject stem cells into the human brain to trigger a process called neurogenesis (the growth of new neural cells), which could combat diseases like Parkinson's, Alzheimer's, and even schizophrenia.
If NeuroNova is the first to develop a drug capable of treating one of several central nervous system disorders − by far the most lucrative after heart disease products − it will have done so not because it raised more money or got more media buzz than the rest. It will have succeeded because the science is solid, and academe, government, and the investment community are supportive. Meanwhile, the United States will look on with envy and wonder how it, a country known for its entrepreneurial innovation, ever got so short-sighted.
(Adapted from http://www.redherring.com/investor/2003/02/biotech021303.html)
De acordo com o texto,
Q2242612
Inglês
Texto associado
From the IPO to the First Trade: Is Underpricing Related to the Trading Mechanism?
Sonia Falconieri, Albert Murphy and Daniel Weaver
As documented by a vast empirical literature, IPOs are characterized by underpricing. Most of the theoretical literature has linked the size of underpricing to the IPO procedure used on the primary market. In this paper, by using a matched sample of NYSE and Nasdaq IPOs, we show that the size of underpricing also depends on the trading method used in the IPO aftermarket.
There are two major methods of opening trading of initial public offerings (IPOs) in the U.S. The NYSE is an order-driven market ....56.... a call auction allows supply and demand to be aggregated (at one location) prior to the start of trading. ....57.... , Nasdaq is a quote-driven market. Dealers can only specify their best quotes, and participants have ....58.... idea of supply and demand away from the inside quotes.
We propose a new proxy for ex ante uncertainty of firm value and test it. Our results show that there is a larger level of uncertainty at the beginning of trading on Nasdaq than on the NYSE. This in turn is associated with larger levels of underpricing for Nasdaq IPOs. We suggest that this may be due to the different informational efficiency of the two trading systems.
(http://www.nyse.com/marketinfo/p1020656068262.html?displayPage=% 2Fmarketinfo%2Fmarketinfo.html)
Para responder à questão, assinale, na folha de respostas, a letra correspondente à alternativa que preenche corretamente a lacuna do texto apresentado (....57....).
Q2242600
Português
Texto associado
A compensação
Não faz muito, li um artigo sobre as pretensões literárias
de Napoleão Bonaparte. Aparentemente, Napoleão era um
escritor frustrado. Tinha escrito contos e poemas na juventude,
escreveu muito sobre política e estratégia militar, e sonhava em
escrever um grande romance. Acreditava-se, mesmo, que
Napoleão considerava a literatura sua verdadeira vocação, e
que foi sua incapacidade de escrever um grande romance e
conquistar uma reputação literária que o levou a escolher uma
alternativa menor, conquistar o mundo.
Não sei se é verdade, mas fiquei pensando no que isto
significa para os escritores de hoje e daqui. Em primeiro lugar,
claro, leva a pensar na enorme importância que tinha a literatura
nos séculos XVIII e XIX, e não apenas na França, onde,
anos depois de Napoleão Bonaparte, um Victor Hugo
empolgaria multidões e faria história não com batalhas e
canhões, mas com a força da palavra escrita, e não só em
conclamações e panfletos, mas, muitas vezes, na forma de
ficção. Não sei se devemos invejar uma época em que
reputações literárias e reputações guerreiras se equivaliam
desta maneira, e em que até a imaginação tinha tanto poder.
Mas acho que podemos invejar, pelo menos um pouco, o que a
literatura tinha então e parece ter perdido: relevância. Se
Napoleão pensava que podia ser tão relevante escrevendo
romances quanto comandando exércitos, e se um Victor Hugo
podia morrer como um dos homens mais relevantes do seu
tempo sem nunca ter trocado a palavra e a imaginação por
armas, então uma pergunta que nenhum escritor daquele tempo
se fazia é essa que nos fazemos o tempo todo: para que serve
a literatura, de que adianta a palavra impressa, onde está a
nossa relevância? Gostávamos de pensar que era através dos
seus escritores e intelectuais que o mundo se pensava e se
entendia, e a experiência humana era racionalizada. O estado
irracional do mundo neste começo de século é a medida do
fracasso desta missão, ou desta ilusão.
Depois que a literatura deixou de ser uma opção tão
vigorosa e vital para um homem de ação quanto a conquista
militar ou política – ou seja, depois que virou opção para
generais e políticos aposentados, mais compensação pela
perda de poder do que poder, e uma ocupação para, enfim,
meros escritores – ela nunca mais recuperou a sua respeitabilidade, na medida em que qualquer poder, por armas ou por
palavras, é respeitável. Hoje a literatura só participa da política,
do poder e da história como instrumento ou cúmplice. E não
pode nem escolher que tipo de cúmplice quer ser. Todos os que
escrevem no Brasil, principalmente os que têm um espaço na
imprensa para fazer sua pequena literatura ou simplesmente
dar seus palpites, têm esta preocupação. Ou deveriam ter. (...)
(Luiz Fernando Veríssimo, Banquete com os deuses. Rio de
Janeiro: Objetiva, 2003, pp. 113-14)
Está clara e correta a articulação entre os tempos verbais
na seguinte frase:
Q2242580
Auditoria
Assinale a alternativa correta, em relação à revisão
externa da auditoria pelos pares, segundo as Normas
Brasileiras de Contabilidade.
Q2242578
Auditoria
A carta de responsabilidade da administração quanto às
informações e dados, bem como à preparação e apresentação das demonstrações contábeis submetidas à auditoria, deve ser emitida com a mesma data
Q2242577
Auditoria
A técnica conhecida como circularização se enquadra no
procedimento básico de auditoria denominado
Q2242576
Auditoria
O conjunto dos papéis de trabalho do auditor
independente, de acordo com as Normas Brasileiras de
Contabilidade, deve ser guardado pelo prazo de
Q2242550
Conhecimentos Bancários
As Debêntures Simples representam:
Q2242530
Conhecimentos Bancários
As debêntures podem ser emitidas com garantia
Q2242529
Conhecimentos Bancários
O prazo de vencimento das debêntures pode ser
Q2242528
Conhecimentos Bancários
A função principal do Agente Fiduciário contratado numa
emissão de debêntures é
Q2242527
Conhecimentos Bancários
A companhia emissora de debêntures pode manter em
circulação
Conheça nossos planos